AZNAstraZenecaRunning, no new patients
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Non-small Cell Lung Cancer NSCLC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 401 (final count)
- Started
- Dec 21, 2018
- Main results expected
- Jan 11, 2021
- Fully finished
- Sep 27, 2026
- Results posted
- Dec 12, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival
Measured over: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03775486 · record last updated 2026-09-11 · checked 2026-11-09 15:47 UTC